N6-Benzyladenosine

N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma[1]-[5].

Product Specifications

CAS Number

[4294-16-0]

Product Name Alternative

Benzyladenosine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adenosine Receptor; Apoptosis; Phytohormone

Type

Natural Products

Related Pathways

Apoptosis; GPCR/G Protein; Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/n6-benzyladenosine.html

Purity

99.72

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@@H](O)[C@H](N2C(N=CN=C3NCC4=CC=CC=C4)=C3N=C2)O[C@@H]1CO

Molecular Formula

C17H19N5O4

Molecular Weight

357.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Kaminek M, et al. Cytokinin activities of N6-benzyladenosine derivatives hydroxylated on the side-chain phenyl ring. Journal of Plant Growth Regulation. 1987. 6 (2) :113.|[2]Castiglioni S, et al. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells. Anticancer Agents Med Chem. 2013 May;13 (4) :672-8. |[3]Mlejnek P. Caspase inhibition and N6-benzyladenosine-induced apoptosis in HL-60 cells. J Cell Biochem. 2001;83 (4) :678-89.|[4]Kim YA, et al. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochem Pharmacol. 2007 May 15;73 (10) :1558-72. |[5]Grimaldi M, et al. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity. Bioorg Chem. 2020 May;98:103449.